- Home
- » Tags
- » Vildagliptin
Top View
- Ertugliflozin As Monotherapy and in Dual Therapy for Treating Type 2 Diabetes [ID1158]
- SGLT2 Inhibitors
- Recommendation from the New Drugs Committee
- Sponsor Novartis Generic Drug Name Vildagliptin (LAF237
- Outcomes of Transition from Premixed and Intensive Insulin Therapies to Insulin Aspart/Degludec Co-Formulation in Type 2 Diabetes Mellitus: a Real-World Experience
- Vildagliptin for the Treatment of Diabetes
- Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin in Vivo S
- Insulin Glargine and Detemir Pioglitazone Exenatide Liraglutide
- Efficacy and Safety of Vildagliptin As an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated with Basal Insulin
- DPP-4 Inhibitors
- 9. Pharmacologic Approaches to Glycemic Treatment
- Comparative Effects of Vildagliptin and Sitagliptin Determined by Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus
- An Evolutionary Perspective on Basal Insulin in Diabetes Treatment
- Two Sporadic Cases of Acute Pancreatitis Associated with Vildagliptin
- Combination of Vildagliptin and Rosiglitazone Ameliorates Nonalcoholic Fatty Liver Disease in C57BL/6 Mice
- Comparison of Efficacy of Add-On Therapy of Vildagliptin
- Vildagliptin: Novel Pharmacological Approach to Treat Type 2 Diabetes
- International Journal of Pharmacy & Life Sciences
- Mechanisms Underlying Cardiovascular Benefits of Sodium Glucose Co-Transporter-2 Inhibitors
- Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients with Type 2 Diabetes a 24-Week, Double-Blind, Randomized Trial
- Dipeptidyl Peptidase-4 Inhibitors Clinical Data and Clinical Implications
- Insulin Degludec/Insulin Aspart (Degludecplus) for Type 2 Diabetes
- Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
- 'Islet Enhancer' for the Treatment of T2DM1 Galvus® (Vildagliptin)
- Pancreatic Β- Cell Effects of Canagliflozin Versus Vildagliptin on Streptozotocin-Induced Type 2 Diabetes Mellitus in Male Albino Rats
- Therapeutic Class Overview Insulins
- Galvus 50 Mg Tablets
- Initiating and Intensifying Insulin Therapy in Patients with Type 2 Diabetes
- In Vitro Study Examining the Activity of Vildagliptin and Sitagliptin Against
- SEC (Endocrinology & Metabolism) Made in Its 87Th Meeting Held On
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients with Type 2 Diabetes a 1-Year, Randomized, Treat-To-Target Trial (BEGIN Once Long)
- Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes
- A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch from Sitagliptin in Patients with Type 2 Diabetes
- In Vitro Complexation of Olmesartan Medoxomil with Dapagliflozin, Vildagliptin and Metformin
- Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below
- Simultaneous Determination of Metformin, Sitagliptin, Saxagliptin, Linagliptin and Vildagliptin in Multicomponent Pharmaceutical Preparations by RP-HPLC
- Ryzodeg, INN-Insulin Degludec/Insulin Aspart
- Original Article Efficacy and Safety of Vildagliptin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis
- Article 9387 1554A664486917b
- C8d0ca740e9fad3f3587dae835c
- Novartis Media Update Guide
- A Comprehensive Review and Perspective on Natural Sources As Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
- DPP-4 Inhibitors Vs. SGLT-2 Inhibitors; Cons and Pros Xourgia E, Papazafiropoulou AK*, Karampousli E and Melidonis A
- Effect of Alogliptin, a DPP-4 Inhibitor, on Markers of Lipid Metabolism In
- Package Leaflet: Information for the Patient Vildagliptin Galenicum 50 Mg Tablets Vildagliptin Read All of This Leaflet Carefull
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26
- FDA Warns That DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain
- Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes
- Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes
- Eucreas, INN-Vildagliptin/Metformin Hydrochloride
- Degludec Is Superior to Glargine in Terms of Daily Glycemic Variability in People with Type 1 Diabetes Mellitus
- Vildagliptin – Benefit Assessment According 1 to § 35A Social Code Book V
- Patterns of Adherence, Persistence, and Switching Among Australians
- Australian Public Assessment Report for Vildagliptin/Metformin Hydrochloride
- Efficacy and Safety of Vildagliptin, Sitagliptin, and Linagliptin As Add-On
- Combined Therapy with Insulin Plus Oral Agents: Is There Any Advantage? an Argument in Favor
- Effects of Dipeptidyl Peptidase-4 Inhibitor in Insulin-Resistant Rats with Myocardial Infarction
- Galvumet 50 Mg/850 Mg Tablets Galvumet 50 Mg/1000 Mg Tablets (Vildagliptin/ Metformin Hydrochloride)
- Vildagliptin: a DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
- Development and Validation of New Stability Indicating Reversed-Phase
- (III) Complexes of Metformin, Dapagliflozin, Vildagliptin And
- New Drugs in Development for the Treatment of Diabetes
- Possibility of Pharmacokinetic Drug Interaction Between a DPP-4 Inhibitor and a SGLT2 Inhibitor